GlassScriptPhysician profile
Hamid Taheri
NPI 1295773679
$501,448.82
in general payments reported to CMS, 2019-2025
67 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $63K · 2021: $59K · 2022: $72K · 2023: $44K · 2024: $104K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Food and Beverage: $19K · Travel and Lodging: $7,882 · Education: $89.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,582.69 |
| Food and Beverage | $19,259.62 |
| Travel and Lodging | $7,881.71 |
| Education | $89.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $127,524.34 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $108,085.21 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $73,940.71 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $71,055.15 | 2020-2025 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53,123.47 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $17,718.57 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $14,577.87 | 2019-2025 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $8,561.38 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $4,269.14 | 2019-2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $3,881.52 | 2019-2023 | Diamondback Coronary |
| Abbott Laboratories | $2,783.13 | 2019-2025 | Xact, Diamondback Peripheral, Acculink |
| Boston Scientific Corporation | $2,119.45 | 2019-2025 | Watchman Access System, Rotapro, Wolverine Coronary Cutting Balloon |
| Novartis Pharmaceuticals Corporation | $1,809.04 | 2019-2025 | |
| Abiomed | $1,803.36 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $926.02 | 2021-2025 | Verquvo, Capvaxive |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $880.74 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Pfizer INC. | $828.32 | 2019-2025 | |
| Medtronic, INC. | $781.48 | 2021-2025 | Symplicity G3, Linq II, Hawkone |
| Recor Medical INC | $703.70 | 2025 | Paradise Ultrasound Renal Denervation System |
| Edwards Lifesciences Corporation | $589.23 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $540.31 | 2023-2024 | Ffrct |
| Scpharmaceuticals INC. | $501.32 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $475.45 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $417.96 | 2022-2025 | |
| Cvrx, INC. | $392.78 | 2022-2025 | Barostim Neo System |
| Atricure, INC. | $337.85 | 2022-2024 | |
| Medtronic Vascular, INC. | $266.49 | 2019-2020 | |
| Bridgebio Pharma, INC. | $248.24 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $221.58 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $195.32 | 2023-2025 | Assure Wcd |
| Philips North America LLC | $184.20 | 2019-2025 | Peripheral Vascular Undivided, Business Operations |
| Zoll Respicardia, INC. | $136.39 | 2021 | |
| Chiesi USA, INC. | $127.18 | 2022-2025 | Kengreal |
| Ionis Pharmaceuticals, INC. | $122.03 | 2025 | Tryngolza |
| Aegerion Pharmaceuticals, INC. | $111.22 | 2019 | |
| Daiichi Sankyo INC. | $100.30 | 2023-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $95.40 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $95.30 | 2023 | Xarelto |
| Cook Medical LLC | $91.45 | 2019-2025 | |
| Qorumpartners | $78.67 | 2022 | |
| Terumo Medical Corporation | $75.34 | 2019-2025 | Angio-Seal |
| Baxter Healthcare | $58.44 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Portola Pharmaceuticals, LLC | $58.17 | 2019 | |
| Gilead Sciences, INC. | $54.98 | 2019 | |
| Shockwave Medical, INC | $54.03 | 2019-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bard Peripheral Vascular, INC. | $53.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $51.28 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $46.98 | 2021-2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Kiniksa Pharmaceuticals International, Plc | $43.09 | 2024 | Arcalyst |
| Cordis US Corp. | $33.48 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $33.10 | 2024 | |
| Cardinal Health 200 LLC | $31.82 | 2019 | |
| Livanova USA, INC. | $24.82 | 2020 | |
| Tactile Systems Technology INC | $22.57 | 2023 | Entre Plus, Flexitouch Plus |
| Arbor Pharmaceuticals, INC. | $22.01 | 2022 | |
| Coala Life INC | $18.80 | 2022 | |
| Cardiofocus, INC. | $17.70 | 2019 | |
| Ekos Corporation | $16.78 | 2019 | |
| Genzyme Corporation | $15.78 | 2019 | |
| Medicomp INC | $15.06 | 2023 | Telepatch Cardiac Monitor |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,706.96 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Taheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.